Who is sponsoring NCT00430638?

NCT00430638 is sponsored by Daiichi Sankyo.

What condition does NCT00430638 study?

NCT00430638 studies Hypertension.

What drugs are being tested in NCT00430638?

Interventions: olmesartan medoxomil + hydrochlorothiazide, if necessary, Placebo.

What is the status of NCT00430638?

NCT00430638 is currently COMPLETED.

Last reviewed 2018-09-04 · How we verify

A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension

NCT00430638 Phase 4 COMPLETED Results posted

This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Details

Lead sponsor	Daiichi Sankyo
Phase	Phase 4
Status	COMPLETED
Enrolment	278
Start date	2006-12
Completion	2007-10

Conditions

Hypertension

Interventions

olmesartan medoxomil + hydrochlorothiazide, if necessary
Placebo

Primary outcomes

Change From Baseline in Mean Systolic Blood Pressure (SBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device. — baseline to 12 weeks
The change from baseline in mean systolic blood pressure (SBP) after 12 weeks of randomized treatment was compared between the olmesartan based treatment group and the placebo treatment group.

Countries

United States